Related Experiment Video
Updated: Jun 14, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children
Marie-Louise von Linstow1, Peter Lotko Pontoppidan, Carl-Heinz Wirsing von König
1Department of Pediatrics, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.
Insights
A study found that a single-component pertussis toxin (PT) vaccine may have limited efficacy in preventing Bordetella pertussis infections in Danish infants. Researchers suggest a multi-component vaccine may be more effective.
Area of Science:
- Immunology
- Pediatrics
- Infectious Diseases
Background:
- Pertussis remains a significant public health concern globally.
- Current monocomponent pertussis toxin (PT) toxoid vaccines are used in some regions.
- Assessing vaccine efficacy against Bordetella pertussis infection is crucial for public health strategies.
Purpose of the Study:
- To evaluate the efficacy of a monocomponent PT toxoid vaccine in Danish infants.
- To estimate the rate of Bordetella pertussis infection in vaccinated infants.
- To inform future vaccination strategies and vaccine development.
Main Methods:
- Sera from 203 1-year-old children vaccinated with a monocomponent PT toxoid vaccine were analyzed for IgA and IgG antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA).
- Antibody levels were correlated with clinical data, including coughing episodes.
- Infection rates were estimated based on IgA antibody responses, considering the known limitations of this immune marker.
Main Results:
- Ten children (5%) showed IgA antibodies to PT, suggesting recent infection, with seven having received three vaccine doses.
- No significant difference in coughing episode duration was observed between PT IgA responders and non-responders.
- The estimated actual Bordetella pertussis infection rate in the cohort was approximately 10%, indicating potential vaccine limitations.
Conclusions:
- The monocomponent PT toxoid vaccine used in Denmark may exhibit limited efficacy in preventing Bordetella pertussis infection in infants.
- A high infection rate suggests a need for further investigation into vaccine effectiveness.
- A prospective study comparing multi-component vaccines with the current monocomponent vaccine is recommended.
Abstract:
We measured IgA and IgG antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in sera from 203 1-year-old children who had received one to three doses of a monocomponent PT toxoid vaccine. Ten children (5%) had IgA antibody to PT indicating recent infection; seven of these children had received three doses of vaccine. PT IgA responders did not have significantly longer coughing episodes than PT IgA non-responders. Since an IgA antibody response occurs in only approximately 50% of infected children, the actual infection rate in our cohort is estimated to approximately 10%. The apparent high Bordetella pertussis infection rate in Danish infants suggests that the monocomponent PT toxoid vaccine used in Denmark has limited efficacy against B. pertussis infection. A prospective immunization study comparing a multi-component vaccine with the present monocomponent PT toxoid vaccine should be undertaken.
More Related Videos
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Related Concept Videos
Respiratory Syncytial Virus Disease
Vaccinations
Diphtheria
Chickenpox
Poliomyelitis